- Nasdaq has suspended trading in Aeterna Zentaris (NASDAQ:AEZS) pending the release of news.
- Update: Through a subsidiary, the company has inked an agreement with Strongbridge Biopharma plc (NASDAQ:SBBP) to commercialize Macrilen (macimoreline) in the U.S. and Canada. Under the terms of the deal, Aeterna will receive $24M upfront and royalties of 15% on net sales up to $75M and 18% on sales above $75M. In addition, it will receive one-time payments per the following:
- $4M on achieving $25M in sales; $10M on $50M in sales; $20M on $100M in sales; $40M on $200M in sales and $100M on $500M in sales.
- FDA approval of Macrilen for pediatric use will trigger a $5M milestone payment to Aeterna from Strongbridge.
- Strongbridge will fund 70% of the costs of a global pediatric development program run by Aeterna with oversight from a joint steering committee.
- Last month, the FDA approved Macrilen for use in the diagnosis of adult growth hormone deficiency.
- Previously: FDA OKs Aeterna Zentaris' Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hours (Dec. 20, 2017)
- Now read: Incyte: Low Expectations, Great Growth, Looks Appealing
Original article